Luca Scrivano

Scientist Drug Product at MICREOS - Den Haag, Zuid Holla, NL

Luca Scrivano's Colleagues at MICREOS
Robin Peterson

Sales Director- North America

Contact Robin Peterson

Bjorn Hendriksen

Senior Technician DSP Drug Product Development

Contact Bjorn Hendriksen

Sofia Feng

Scientist and Business Development

Contact Sofia Feng

View All Luca Scrivano's Colleagues
Luca Scrivano's Contact Details
HQ
N/A
Location
Utrecht,Utrecht,Netherlands
Company
MICREOS
Luca Scrivano's Company Details
MICREOS logo, MICREOS contact details

MICREOS

Den Haag, Zuid Holla, NL • 100 - 249 Employees
BioTech/Drugs

According to the World Health Organization (WHO) emergence of antibiotic-resistant 'superbugs' is now a global concern, which can spell the end of modern medicine and a return to the days when routine operations, simple wounds or straightforward infections were potentially life-threatening. On the other hand scientists have come to realize that the vast majority of bacteria is beneficial and should be left intact. Antibiotics do not distinguish between bad and good bacteria and their use can lead to side effects and resistance. Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. With Micreos' endolysin technology, for the first time it is possible to kill only the unwanted bacteria - including antibiotic resistant strains such as MRSA - while leaving our microbiome - comprising billions of beneficial bacteria on our skin and in our gut - intact. In addition, research shows that the use of endolysins does not induce resistance. This unlocks a completely new approach in dealing with the bacteria around us: killing the bad bacteria and preserving the microbiome. Micreos' Staphefekt SA.100 is an enzyme (endolysin), that targets only Staphylococcus aureus. Marketed under the Gladskin brand, it is the world's first endolysin registered for human use and has had a life-changing impact for thousands of people suffering from inflammatory skin conditions such as eczema, inflammatory acne and rosacea and resistant wound infections (see www.gladskin.com). A series of pharmaceutical products based on the endolysin XZ.700 - also targeting S. aureus - is in clinical development. First indications include: atopic dermatitis, diabetic wound infections and folliculitis. Micreos has also developed FDA-approved food safety products: 'Phageguard S' against Salmonella and 'Phageguard L' against Listeria monocytogenes, which is especially dangerous for pregnant women and for the elderly and immuno-compromised (www.phageguard.com).

Research & Development Product introduction World class phage production Contract manufacturing Phage Technology Endolysin Technology Phage production Endolysin Production Microbiome Staphylococcus aureus MRSA Human Health Dermatology Eczema Rosacea Acne Folliculitis Diabetic Wound Infections Food Safety Listeria Salmonella Intracellular Staph Phageguard Gladskin
Details about MICREOS
Frequently Asked Questions about Luca Scrivano
Luca Scrivano currently works for MICREOS.
Luca Scrivano's role at MICREOS is Scientist Drug Product.
Luca Scrivano's email address is ***@micreos.com. To view Luca Scrivano's full email address, please signup to ConnectPlex.
Luca Scrivano works in the Research industry.
Luca Scrivano's colleagues at MICREOS are Robin Peterson, Bjorn Hendriksen, Nadine Heinrich, Alessandra Moncho, Melanie Stinn, Sofia Feng, Johan Frieling and others.
Luca Scrivano's phone number is N/A
See more information about Luca Scrivano